Barclays
VIRX

Barclays’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Barclays’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,668
Closed -$1.45K – 5538
2024
Q2 		$1.45K Hold
2,668
– – ﹤0.01% 4664
2024
Q1 		$2.72K Hold
2,668
– – ﹤0.01% 4899
2023
Q4 		$1.52K Hold
2,668
– – ﹤0.01% 5090
2023
Q3 		$2.77K Hold
2,668
– – ﹤0.01% 4436
2023
Q2 		$3.76K Hold
2,668
– – ﹤0.01% 4295
2023
Q1 		$4.24K Sell
2,668
-83
-3% -$151 ﹤0.01% 4842
2022
Q4 		$4.02K Sell
2,751
-2,093
-43% -$6.11K ﹤0.01% 5029
2022
Q3 		$20K Buy
4,844
+2,176
+82% +$9.21K ﹤0.01% 4071
2022
Q2 		$10K Sell
2,668
-5,886
-69% -$16.8K ﹤0.01% 4642
2022
Q1 		$41K Buy
+8,554
New +$25.8K ﹤0.01% 4198
2018
Q2 		– Hold
0
– – – 7355
2018
Q1 		– Hold
0
– – – 7401
2016
Q4 		– Hold
0
– – – 6883
2016
Q3 		– Hold
0
– – – 6839
2016
Q2 		– Hold
0
– – – 6692
2016
Q1 		– Hold
0
– – – 6493
2015
Q4 		– Hold
0
– – – 6687
2015
Q3 		– Hold
0
– – – 7104
2015
Q2 		– Sell
-413
Closed -$219K – 7249
2015
Q1 		$173K Buy
413
+394
+2,074% +$199K ﹤0.01% 4457
2014
Q4 		$8K Sell
19
-373
-95% -$168K ﹤0.01% 6835
2014
Q3 		$577K Buy
392
+163
+71% +$236K ﹤0.01% 3829
2014
Q2 		$289K Sell
229
-182
-44% -$211K ﹤0.01% 4467
2014
Q1 		$519K Buy
411
+199
+94% +$231K ﹤0.01% 3925
2013
Q4 		$179K Buy
212
+206
+3,433% +$213K ﹤0.01% 5120
2013
Q3 		$5K Sell
6
-71
-92% -$75.9K ﹤0.01% 6996
2013
Q2 		$84K Buy
+77
New +$85.8K ﹤0.01% 5924

Other funds holding VIRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Barclays's VIRX Position: Q3 2024 in Review

Barclays sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2024, closing a stake of 2,668 shares — an estimated $1.45K sold.

Barclays first reported a position in VIRX in Q2 2013 and held it in 18 quarters. The position peaked at $577K in Q3 2014. 38 funds tracked by Wall St. Rank hold VIRX as of Q3 2024.

  • Barclays reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Barclays sold 2,668 Viracta Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $1.45K.
  • Barclays first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
  • Barclays's Viracta Therapeutics, Inc. Common Stock position peaked at $577K in Q3 2014.
  • 38 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.